Sol-Gel Technologies (NASDAQ: SLGL) received a significant boost as HC Wainwright raised its price target from $6.00 to an impressive $50.00, according to a research note published on Monday. This adjustment reflects a growing confidence in the company’s future performance, with HC Wainwright maintaining a “buy” rating on the stock. The firm also provided estimates for Sol-Gel Technologies’ earnings over the next several quarters, projecting a loss of $2.09 per share for Q3 2025 and a return to profitability with earnings of $0.40 per share in Q4 2025.
Analysts have recently been vocal about Sol-Gel Technologies. Weiss Ratings reaffirmed a “hold (C-)” rating on October 8, while Wall Street Zen upgraded the stock to a “buy” rating on September 13. Currently, one analyst has rated the stock as a buy, with another offering a hold rating. MarketBeat.com noted that the overall consensus rating stands at “Moderate Buy,” with the average target price aligning with HC Wainwright’s estimate at $50.00.
Financial Performance and Analyst Insights
Sol-Gel Technologies last reported its quarterly earnings on August 15, 2023, revealing earnings per share of $4.17. This figure surpassed analysts’ predictions, which had anticipated a loss of $0.67 per share, indicating a substantial positive deviation of $4.84. The company’s revenue for the quarter reached $17.26 million, significantly exceeding the expected $2.86 million.
Despite the positive earnings report, Sol-Gel Technologies continues to face challenges, as evidenced by a negative return on equity of 11.80% and a net margin of 14.25%. Analysts forecast that the company will post an average earnings per share of -0.28 for the current fiscal year.
About Sol-Gel Technologies
Based in Israel, Sol-Gel Technologies Ltd. specializes in developing topical dermatological treatments for patients with severe skin conditions. Its product portfolio includes Twyneo, a once-daily, non-antibiotic topical cream aimed at treating acne vulgaris, and Epsolay, designed for the treatment of papulopustular rosacea. The company’s innovative approach to dermatology positions it favorably in a competitive market.
As Sol-Gel Technologies continues to gain traction with analysts, stakeholders will be keenly observing how these developments impact its stock performance and financial health in the coming quarters.
